Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.3M Buy
129,816
+46,785
+56% +$5.29M ﹤0.01% 1649
2026
Q1
$9.25M Buy
83,031
+15,366
+23% +$1.82M ﹤0.01% 1980
2025
Q4
$9.12M Buy
67,665
+9,047
+15% +$987K ﹤0.01% 1985
2025
Q3
$4.98M Buy
+58,618
New +$3.59M ﹤0.01% 2459
2025
Q2
Sell
-19,000
Closed -$119K 3956
2025
Q1
$119K Buy
19,000
+7,332
+63% +$49.6K ﹤0.01% 3859
2024
Q4
$85.4K Buy
+11,668
New +$107K ﹤0.01% 3968

Other funds holding ABVX

Ameriprise's ABVX Position: Q2 2026 in Review

Ameriprise increased its Abivax (ABVX) stake by 56% in Q2 2026, buying an estimated $5.29M and bringing the position to 129,816 shares worth $17.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1649.

Ameriprise first reported a position in ABVX in Q4 2024 and has held it in 6 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Ameriprise held 129,816 shares of Abivax worth $17.3M as of Q2 2026.
  • Ameriprise bought 46,785 Abivax shares in Q2 2026, an estimated $5.29M.
  • Abivax made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1649 holding.
  • Ameriprise first reported a position in Abivax in Q4 2024 and has held it in 6 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.